Sex: F
Vaccine: COVID19
Symptoms: Eye symptom, Intraocular pressure increased, Ocular hyperaemia, Rash, Visual impairment
Clinical narrative: rash on face; presure in eyes dangerously high; change in her vision in her left eye; itching and burning of the eyes; eyes were red; eyes were red and inflamed; Corneas split; eye swollen shut; eye symptoms; itching and burning of the eyes; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of OCULAR HYPERAEMIA (eyes were red), EYE INFLAMMATION (eyes were red and inflamed), CORNEAL DISORDER (Corneas split), EYE SWELLING (eye swollen shut) and RASH (rash on face) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Dry eye, Allergy NOS, Penicillin allergy and Drug allergy (Prednisone). Concomitant products included LIFITEGRAST (XIIDRA) for Eye allergy.    On 02-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-May-2021, the patient experienced EYE SYMPTOM (eye symptoms). In May 2021, the patient experienced EYE IRRITATION (itching and burning of the eyes). On an unknown date, the patient experienced OCULAR HYPERAEMIA (eyes were red), EYE INFLAMMATION (eyes were red and inflamed), CORNEAL DISORDER (Corneas split), EYE SWELLING (eye swollen shut), RASH (rash on face), INTRAOCULAR PRESSURE INCREASED (presure in eyes dangerously high), VISUAL IMPAIRMENT (change in her vision in her left eye) and EYE PRURITUS (itching and burning of the eyes). The patient was treated with ANTIBIOTICS for Eye symptom, at an unspecified dose and frequency; PREDNISONE (conjunctival) in May 2021 for Eye redness, at a dose of 1 UNK; LOTEPREDNOL ETABONATE (LOTEMAX) at an unspecified dose and frequency; PROPYLENE GLYCOL (SYSTANE BALANCE) ongoing since an unknown date at an unspecified dose and frequency; MUPIROCIN (BACTROBAN [MUPIROCIN]) at an unspecified dose and frequency; TRAVOPROST (TRAVATAN) (intraocular) on 31-May-2021 for Intraocular pressure increased, at an unspecified dose and frequency; ERYTHROMYCIN in May 2021 for Eye symptom, at an unspecified dose and frequency; NEPAFENAC (ILEVRO) ongoing since an unknown date for Eye symptom, at an unspecified dose and frequency; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) for Eye pruritus and Eye irritation, at a dose of 1 dosage form and ANTIBIOTICS (oral) from May 2021 to June 2021 for Eye symptom, at a dose of 1 dosage form. At the time of the report, OCULAR HYPERAEMIA (eyes were red), EYE INFLAMMATION (eyes were red and inflamed), CORNEAL DISORDER (Corneas split), EYE SWELLING (eye swollen shut), RASH (rash on face), INTRAOCULAR PRESSURE INCREASED (presure in eyes dangerously high), EYE PRURITUS (itching and burning of the eyes), EYE IRRITATION (itching and burning of the eyes) and EYE SYMPTOM (eye symptoms) outcome was unknown and VISUAL IMPAIRMENT (change in her vision in her left eye) had not resolved.            Treatment also included a mild moisturizer cold packs on eyes and contact patches over the eyes.